1 Moreover, segmentation and
dosimetric accuracy are within or smaller than the inter
2 body residence time was calculated after the
dosimetric administration from total-body counts obtaine
3 Prone was associated with a
dosimetric advantage in most patients.
4 The relative
dosimetric advantage of a given radiopharmaceutical comp
5 We evaluate the
dosimetric advantage of prone setup for the right breast
6 Dosimetric advantage of prone was assessed by the reduct
7 The CE emitter 117mSn offers a large
dosimetric advantage over energetic beta-particle emitte
8 e emitter 33P appears to offer a substantial
dosimetric advantage over energetic beta-particle emitte
9 With improved targeting and the
dosimetric advantages of proton beam therapy, we aimed t
10 tions as a logical next step to maximize the
dosimetric advantages of proton therapy.
11 However, full exploitation of the
dosimetric advantages of PT is not yet possible due to r
12 These probes or
dosimetric agents demonstrated good selectivity, two-sig
13 Dosimetric analyses indicate that scavenging enzymes bar
14 The pharmacokinetic and
dosimetric analyses were further determined using WinNon
15 ive data obtained are useful for kinetic and
dosimetric analyses, which may be applied to study other
16 Our
dosimetric analysis demonstrated a (64)Cu effective dose
17 d pretreatment (131)I-omburtamab imaging and
dosimetric analysis in patients before therapy.
18 Conclusion SPECT/CT
dosimetric analysis of (99m)Tc-MAA injected via the bron
19 The
dosimetric analysis of 123I-IAZA in 6 healthy volunteers
20 SPECT resolution is not sufficient to enable
dosimetric analysis of anatomic features of the thicknes
21 was derived from clinical experience, and a
dosimetric analysis of lung and tumor absorbed dose woul
22 Dosimetric analysis showed that (225)Ac-treated metastas
23 Dosimetric analysis showed the binding affinity of amelo
24 Dosimetric analysis was also performed for a lung-surfac
25 administered activity levels were guided by
dosimetric analysis.
26 ermined in anesthetized dogs as well as by a
dosimetric analysis.
27 of this work was to investigate the relevant
dosimetric and luminescent properties of MgO:Li3%,Ce0.03
28 study aimed at identifying patient-specific
dosimetric and nondosimetric factors predicting outcome
29 So, GAT provides the greatest
dosimetric and radiobiological benefits for liver tumors
30 Our study aimed to explore the
dosimetric and radiobiological benefits of various respi
31 son's correlations between the reductions in
dosimetric and radiobiological parameters and tumor moti
32 Dosimetric and radiobiological parameters were recorded
33 by the region-of-interest method, after both
dosimetric and therapeutic administrations.
34 ve of 47 patients were treated with a single
dosimetric and therapeutic dose.
35 nlabeled antibody was given prior to labeled
dosimetric and therapeutic doses to improve biodistribut
36 MR and CT imaging,
dosimetric,
and demographic features of patients were us
37 representative distribution of demographic,
dosimetric,
and radiomic features in both sets.
38 A single-cell
dosimetric approach is required to evaluate the efficacy
39 The workshop focused on current
dosimetric approaches for clinical trials, strategies un
40 For
dosimetric assessment, whole-body planar scintigraphy wa
41 Results:
Dosimetric assessments were evaluated in 20 patients.
42 Conclusion: The
dosimetric behavior we report over different cycles and
43 f SFGSGFGGGY to amelogenins was confirmed by
dosimetric binding of amelogenins or TRAP with [(3)H]pep
44 nity of CK14 and amelogenin was confirmed by
dosimetric binding of CK14 to recombinant amelogenin (rM
45 The GlcNAc affinity was confirmed by
dosimetric binding of rM179 with [14C]GlcNAc, specific b
46 Minimal toxicity,
dosimetric calculations and clinical assessment indicate
47 erent time points after injection to perform
dosimetric calculations and to determine the optimal ima
48 Dosimetric calculations are performed with an increasing
49 Dosimetric calculations based on the measured time-integ
50 Biodistribution assays and
dosimetric calculations established that scVEGF/(177)Lu
51 ive study were used to perform retrospective
dosimetric calculations for (131)I therapy for the norma
52 Dosimetric calculations in relation to PRRT have been co
53 Even though
dosimetric calculations reveal that the doses applied in
54 The
dosimetric calculations show that further optimization i
55 Conclusion: Our human PET/CT-based
dosimetric calculations show that the effective radiatio
56 olabeled exendin in humans, and we performed
dosimetric calculations to estimate the maximum absorbed
57 Dosimetric calculations were performed using the MIRD fo
58 Dosimetric calculations, assuming nonreceptor targeting,
59 enuation correction and allows more accurate
dosimetric calculations.
60 The
dosimetric challenge in grid therapy is the mystery behi
61 This study aimed to investigate the
dosimetric characteristics of an isocentrically shielded
62 rlo simulation was performed to estimate the
dosimetric characteristics of the SAFI treatment beams.
63 the volumetric modulated arc therapy (VMAT)
dosimetric comparison between Halcyon ring gantry and Tr
64 maging agents, light delivery components and
dosimetric components.
65 e radiotherapy and to evaluate the resulting
dosimetric consequences to surrounding organs at risk.
66 ATE therapy was rare and resulted in minimal
dosimetric consequences, with absorbed doses at the infu
67 Our data demonstrates that without proper
dosimetric corrections, studies using low energy electro
68 , the photoactivating light and to establish
dosimetric correlation of light and drug parameters to P
69 MVs
dosimetric correlation was investigated using dose volum
70 Retrospective
dosimetric correlations were conducted and related to re
71 nformal optimized planning provided improved
dosimetric coverage compared with standard techniques.
72 Each series looks at various
dosimetric cutpoints that predict for freedom from bioch
73 Yet,
dosimetric data acquired for 4 d or more may be insuffic
74 safety, and tolerability, as well as provide
dosimetric data and evaluate the imaging properties, of
75 enerate and make freely available a range of
dosimetric data and tools.
76 ional teams to produce and compare traceable
dosimetric data using 6 of the most popular Monte Carlo
77 The
dosimetric database has added value in the development o
78 The generated
dosimetric database of radiotracers using new-generation
79 vity that can safely be administered without
dosimetric determination of the maximum tolerable activi
80 The therapy is delivered in 2 parts, a
dosimetric dose and a therapeutic dose.
81 ioimmunotherapy regimen is administered as a
dosimetric dose followed by a therapeutic dose.
82 The biodistribution of the
dosimetric dose is assessed by quantitative calculations
83 Nine patients received a
dosimetric dose of 370 MBq (10 mCi).
84 assigned to receive iodine-131 tositumomab (
dosimetric dose of 5 mCi on day -19 and therapeutic dose
85 This consisted of a
dosimetric dose of tositumomab and 131I-labeled tositumo
86 The single therapeutic dose following a
dosimetric dose was adjusted to give the same total body
87 A single
dosimetric dose was followed at 7 to 14 days by the pati
88 mnants after surgery, even though the median
dosimetric dose was only 40 MBq.
89 ells/mm(3)) was given 7 to 14 days after the
dosimetric dose.
90 ) based on the clearance rate of a preceding
dosimetric dose.
91 sing NHL were first studied with one or more
dosimetric doses of approximately 5 mCi of 1311 anti-B1
92 Six patients received
dosimetric doses only.
93 their frequency, impact on patient care, and
dosimetric effects.
94 We also briefly discuss the
dosimetric equivalent of biomarkers to help bring a prec
95 Dosimetric estimates based on the thyroid volume to be t
96 once during therapy with SPECT to assist in
dosimetric estimation.
97 patient-dependent phantoms for more accurate
dosimetric estimations relative to standard reference do
98 Dosimetric estimations suggested that the insulinoma abs
99 s of improving therapeutic outcomes, such as
dosimetric estimations, high-dose therapies, multiple fr
100 Dosimetric evaluation at the luminal mucosa performed on
101 We report the
dosimetric evaluation of prostate-specific membrane anti
102 ng CT, treatment plan design and delivery, a
dosimetric evaluation of the IRRAMICE was conducted.
103 The
dosimetric evaluation of the mouse phantom involved comp
104 We also perform a
dosimetric evaluation of the treatment plans based on pC
105 Dosimetric evaluation was performed for main organs and
106 hat OR, CR, and PFS were associated with the
dosimetric factors and equivalent biologic effect.
107 gnificantly with almost all of the evaluated
dosimetric factors, including equivalent biologic effect
108 biological, physical, genetic, clinical, and
dosimetric factors.
109 However, further
dosimetric features of these two parameters are necessar
110 The
dosimetric goal was 85 Gy in 7 days to a conformal volum
111 This series of five
dosimetric head and brain models will allow more precise
112 sensor arrays based on these AgNP inks offer
dosimetric identification of acidic and oxidizing gases
113 5 or > 4:1 for EudraCT no. 2007-007241-12 at
dosimetric imaging).
114 The
dosimetric implication of these results may be significa
115 igated as a tool for providing parameters of
dosimetric importance during radionuclide therapy.
116 agents and, from these data, to estimate the
dosimetric improvement to be expected from use of the mo
117 ty indicators for the CATPHAN 600 phantom; -
dosimetric indicators of exposure (DLP i CTDIvol).
118 porate clinical, biomarker, image-based, and
dosimetric information in theranostic digital twins (TDT
119 may hold critical diagnostic, treatment, or
dosimetric information that impacts patient management.
120 o (MC) approach is provided to resolving the
dosimetric issues.
121 omab and (131)I-tositumomab therapy included
dosimetric (
low activity) and therapeutic (high activity
122 ance, utilizing both control point tests and
dosimetric measurements are presented.
123 his raises concerns about the reliability of
dosimetric measurements in CK-SRS radiobiological studie
124 Dosimetric measurements were performed with thermolumine
125 dy dose of radiation, including a simplified
dosimetric method based on just three data points, are d
126 orrespondence is not reached either with the
dosimetric method or with either method in combination w
127 ionship in a manner not predicted by current
dosimetric methodologies.
128 The aim of this work was to develop
dosimetric methods and calculate tumor-absorbed radiatio
129 All three
dosimetric methods yielded bladder and rectal doses high
130 A
dosimetric model describing both high-rate and low-rate
131 A substantial revision to the
dosimetric model of the adult head and brain originally
132 Nuclear Medicine recently adopted a detailed
dosimetric model of the head and brain for the adult.
133 used for the development of a biokinetic and
dosimetric model.
134 sion: Our results demonstrated that accurate
dosimetric modeling is crucial to establishing dose-resp
135 ques, better methods for pharmacokinetic and
dosimetric modeling, and new methods of isotope delivery
136 teams, will extend data production to other
dosimetric models and implement new free features, such
137 (ICRP) is an organization that also supplies
dosimetric models and technical data, for use in providi
138 trabecular bone to define 3-dimensional (3D)
dosimetric models in which explicit spatial distribution
139 Current
dosimetric models of the brain and head lack the anatomi
140 Current single-region
dosimetric models of the kidneys, however, force the ass
141 The development of reliable
dosimetric models will facilitate patient-specific presc
142 sorbed fractions (SAFs) or S values based on
dosimetric models.
143 ity concentration ratio determinations for 2
dosimetric models: using both male and female and male-o
144 approaches may alleviate the consequences of
dosimetric nonuniformity.
145 cal evidence of an association between other
dosimetric or imaging parameters and the lesion or patie
146 ith direct dose calculations using published
dosimetric organ values for (131)I-MIBG and (90)Y-DOTATO
147 icate that mean dose may be used as the sole
dosimetric parameter on the lesion level.
148 ical analyses compared retained activity and
dosimetric parameters between extravasation and control
149 , factors impacting disease progression, and
dosimetric parameters impacting treatment toxicity.
150 Dosimetric parameters including V15, V20, V30 (percent l
151 The study aimed to compare the
dosimetric parameters to target dose coverage and the cr
152 a enzyme-linked immunosorbent assay, and key
dosimetric parameters were derived from posttreatment (9
153 CT imaging and
dosimetric parameters were found to be poor predictors o
154 For
dosimetric parameters, compared to Plan(AC), Plan(GAT) f
155 geneity index, conformity index, and various
dosimetric parameters.
156 We investigated pharmacokinetics,
dosimetric patterns, and absorbed dose (AD)-effect corre
157 macrophages, results show that the achieved
dosimetric performance is comparable with relatively exp
158 Surface dose was estimated on a CT
dosimetric phantom by using thermoluminescent dosimetric
159 n facilitate both placement verification and
dosimetric planning for gynecologic brachytherapy.
160 images for device placement verification and
dosimetric planning for gynecologic brachytherapy.
161 From a
dosimetric point of view, an administered dose of 200 MB
162 r pre-treatment dose verification, improving
dosimetric precision while offering a cost-efficient sol
163 The favorable safety, imaging, and
dosimetric profile makes (18)F-FET-betaAG-TOCA a promisi
164 [(68)Ga]S02-GIP-T4 demonstrated a safe
dosimetric profile, allowing for repeated studies in hum
165 These estimates were used to generate
dosimetric projections for radioimmunotherapy with (90)Y
166 Dosimetric projections for radioimmunotherapy with (90)Y
167 cal 99mTc-EC-C225 appears to have reasonable
dosimetric properties for a diagnostic nuclear medicine
168 used to evaluate tracer biodistribution and
dosimetric properties, time-activity curves, and the sta
169 adiotracers with optimal pharmacokinetic and
dosimetric properties.
170 A standard
dosimetric protocol was defined, and PLANETDose (version
171 a and scaled from 111In-CC49 to 90Y-CC49 for
dosimetric purposes.
172 king them potential radiation biomarkers for
dosimetric purposes.
173 A number of
dosimetric quantifiers have been described.
174 s review, we will focus on the importance of
dosimetric quantifiers in predicting freedom from bioche
175 chemical recurrence and one or both of these
dosimetric quantifiers.
176 he tumor-absorbed doses (ADs), how different
dosimetric quantities evolve over the treatment cycles,
177 genome organisation and couple them to nano-
dosimetric radiation track structure modelling to predic
178 This resulted in personnel radiation
dosimetric readings below measurable levels in all cases
179 The
dosimetric relationship between the human intake dose of
180 stic, systematic understanding of how such a
dosimetric relationship depends on fundamental chemical
181 Statistically significant
dosimetric relationships were established with cataract,
182 reference radiochemical was quantitated as a
dosimetric relative advantage factor (RAF).
183 es the sparing of BS/SC without compromising
dosimetric requirements of other involved structures for
184 Results: Initial
dosimetric results for organs (liver and kidneys) and le
185 stigate differences between patient-specific
dosimetric results obtained using Monte Carlo methodolog
186 tumors is largely based on data derived from
dosimetric,
retrospective, or small prospective studies.
187 the population and the environment using the
dosimetric scheme of the WHO and the interactive tool ER
188 uring is consistent with a mechanism for the
dosimetric sensing of NO2 and other reactive gases by Cu
189 The
dosimetric sensors are selective to ppm levels of CO and
190 These nano-
dosimetric simulations are highly dependent on geometry
191 tumor dose uniformity (11.0% vs. 14.3%), and
dosimetric spread between boost and non-boost targets (D
192 (90)Y
dosimetric studies are challenging because of the lack o
193 Conclusion:
Dosimetric studies have assumed equivalence between (90)
194 ificity testing, in vivo biodistribution and
dosimetric studies were performed in healthy nude mice v
195 Results: In total, 35
dosimetric studies were performed in patients with mostl
196 Twelve consecutive patients referred for a
dosimetric study and subsequent radioiodine treatment of
197 thods: The clinical dataset consisted of the
dosimetric study of a patient administered with [(177)Lu
198 the comparative study and forty-four in the
dosimetric study.
199 l is an image-guided personalized predictive
dosimetric technique developed by our institution, integ
200 nately, assessing the dose rates by standard
dosimetric techniques has been challenging.
201 However,
dosimetric thresholds for toxicity to these tissues from
202 osimetric phantom by using thermoluminescent
dosimetric (
TLD) and CT pencil chamber measurements.
203 implement new free features, such as online
dosimetric tools and patient-specific absorbed dose calc
204 univariate analysis, there were no tumor or
dosimetric treatment characteristics that were found to
205 experiments were performed to determine the
dosimetric trends of PS expression caused by nsPEF as a
206 n Radiological Protection do not incorporate
dosimetric uncertainty.
207 ) as 450 L/kg lipid, which is independent of
dosimetric units.
208 age only one half of that predicted from the
dosimetric uptake in thyroid remnants after surgery, eve
209 n clinical trial of PCa and showed favorable
dosimetric values.
210 ning, the results of which were analyzed for
dosimetric variability, as well as for quality assurance
211 No differences in
dosimetric variables were observed for different compres